(Q35113837)

6 August 2017

1 reference

title

Hypersensitivity and idiosyncratic reactions to oxaliplatin. (English)

1 reference

6 August 2017

1 reference

Rebecca R Thomas

1

1 reference

6 August 2017

Mary G Quinn

series ordinal

2

1 reference

6 August 2017

Barbara Schuler

series ordinal

3

1 reference

6 August 2017

Jean L Grem

series ordinal

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

97

1 reference

6 August 2017

issue

9

1 reference

6 August 2017

page(s)

2301-2307

1 reference

Clinical features of hypersensitivity reactions to carboplatin

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Severe anaphylactic reactions to oxaliplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Anaphylaxis after oxaliplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Anaphylactic reaction to oxaliplatin: a case report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Reaction after oxaliplatin--prevention with corticosteroids?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Idiosyncratic reaction after oxaliplatin infusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Human bone marrow myeloma cells express RANKL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Development and implementation of a carboplatin desensitization protocol for children with neurofibromatosis, type 1 and hypersensitivity reactions in an outpatient oncology clinic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11379

7 January 2021

Identifiers

DOI

10.1002/CNCR.11379

1 reference

6 August 2017

1 reference